SCINAI IMMUNOTHERAPEUTICS LTD. Cash Flows From Used In Financing Activities
SCINAI IMMUNOTHERAPEUTICS LTD. (SCNI) reported Cash Flows From Used In Financing Activities of -ILS 468.00 thousand for the 3-month period ending 2022-06-30, per its 6-K/A filed 2022-08-29.
Discontinued › Cash Flow › Financing Activities
ifrs-full:CashFlowsFromUsedInFinancingActivities · last filed 2022-08-29
- SCINAI IMMUNOTHERAPEUTICS LTD. cash flows from used in financing activities for the quarter ending 2022-06-30 was -468.00K ILS.
- SCINAI IMMUNOTHERAPEUTICS LTD. cash flows from used in financing activities for the quarter ending 2021-12-31 was 27.27M ILS.
- SCINAI IMMUNOTHERAPEUTICS LTD. cash flows from used in financing activities for the quarter ending 2021-09-30 was -988.00K ILS.
- SCINAI IMMUNOTHERAPEUTICS LTD. cash flows from used in financing activities for the quarter ending 2021-06-30 was -317.00K ILS, a 103.16% decline year-over-year.
ILS
| Period end | Cash Flows From Used In Financing Activities 3 month | Cash Flows From Used In Financing Activities 6 month | Cash Flows From Used In Financing Activities 9 month | Cash Flows From Used In Financing Activities 12 month |
|---|---|---|---|---|
| 2022-06-30 | -468.00K ILS 6-K/A · filed 2022-08-29 | -781.00K ILS 6-K/A · filed 2022-08-29 | ||
| 2021-12-31 | 27.27M ILS derived: 6-K/A 12 month − 6-K/A 9 month · filed 2022-08-29 | 26.28M ILS derived: sum of 2 quarters · filed 2022-08-29 | 25.96M ILS derived: sum of 3 quarters · filed 2022-08-29 | 67.78M ILS 6-K/A · filed 2022-08-29 |
| 2021-09-30 | -988.00K ILS 6-K/A · filed 2021-12-27 | -1.30M ILS derived: sum of 2 quarters · filed 2022-08-29 | 40.52M ILS 6-K/A · filed 2021-12-27 | |
| 2021-06-30 | -317.00K ILS 6-K/A · filed 2022-08-29 | 41.51M ILS 6-K/A · filed 2022-08-29 | ||
| 2020-12-31 | -312.00K ILS derived: 20-F 12 month − 6-K/A 9 month · filed 2022-03-28 | -452.00K ILS derived: sum of 2 quarters · filed 2022-03-28 | 9.58M ILS derived: sum of 3 quarters · filed 2022-03-28 | 13.72M ILS 20-F · filed 2022-03-28 |
| 2020-09-30 | -140.00K ILS 6-K/A · filed 2021-12-27 | 9.89M ILS derived: sum of 2 quarters · filed 2021-12-27 | 14.03M ILS 6-K/A · filed 2021-12-27 | |
| 2020-06-30 | 10.03M ILS 6-K · filed 2020-10-02 | 14.17M ILS 6-K · filed 2020-10-02 | ||
| 2019-12-31 | 15.58M ILS derived: 20-F 12 month − 6-K 9 month · filed 2022-03-28 | 85.66M ILS derived: sum of 2 quarters · filed 2022-03-28 | 85.53M ILS derived: sum of 3 quarters · filed 2022-03-28 | 85.21M ILS 20-F · filed 2022-03-28 |
| 2019-09-30 | 70.08M ILS 6-K · filed 2021-01-28 | 69.95M ILS derived: sum of 2 quarters · filed 2021-01-28 | 69.64M ILS 6-K · filed 2021-01-28 | |
| 2019-06-30 | -127.00K ILS 6-K · filed 2020-10-02 | -441.00K ILS 6-K · filed 2020-10-02 | ||
| 2018-12-31 | 84.32M ILS 20-F · filed 2021-05-13 | |||
| 2017-12-31 | 61.84M ILS 20-F · filed 2020-06-12 | |||
| 2015-12-31 | 33.75M ILS 20-F · filed 2018-04-30 |
USD
| Period end | Cash Flows From Used In Financing Activities 3 month | Cash Flows From Used In Financing Activities 6 month | Cash Flows From Used In Financing Activities 9 month | Cash Flows From Used In Financing Activities 12 month |
|---|---|---|---|---|
| 2022-06-30 | -$223.00K 6-K/A · filed 2022-08-29 | |||
| 2021-12-31 | $9.25M derived: 20-F 12 month − 6-K/A 9 month · filed 2022-03-28 | $21.80M 20-F · filed 2022-03-28 | ||
| 2021-09-30 | $12.55M 6-K/A · filed 2021-12-27 | |||
| 2020-12-31 | $4.27M 20-F · filed 2021-05-13 | |||
| 2017-12-31 | $17.84M 20-F · filed 2018-04-30 |